Efficacy of trilostane for the treatment of equine Cushing's syndrome

Equine Veterinary Journal

Volumn 35, Issue 4, 2003, Pages 414-418

  McGowan, C M ^a   Neiger, R ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Cortisol; Horse; Hyperadrenocorticism; Laminitis; Pony; Trilostane

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE; PROTIRELIN; TRILOSTANE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROSTANOLONE; CORTICOTROPIN; DRUG DERIVATIVE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CUSHING DISEASE; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; HORSE DISEASE; INFLAMMATION; LETHARGY; NONHUMAN; PATHOPHYSIOLOGY; POLYDIPSIA; POLYURIA; PROVOCATION TEST; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ANIMAL; ANIMAL DISEASE; BLOOD; CUSHING SYNDROME; DRUG ANTAGONISM; FEMALE; HORSE; MALE; SAFETY;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

3-HYDROXYSTEROID DEHYDROGENASES; ADRENOCORTICOTROPIC HORMONE; ANIMALS; CUSHING SYNDROME; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FEMALE; HORSE DISEASES; HORSES; HYDROCORTISONE; MALE; SAFETY; TREATMENT OUTCOME;

EID: 0242303702     PISSN: 04251644     EISSN: None     Source Type: Journal    
DOI: 10.2746/042516403776014271     Document Type: Article

References (21)

1. Andrews, F.M., Eiler, H., Oliver, J.W., Fecteau, K.A., Green, E.M. and McCracken, M. (1997) Diagnosis of pituitary adenoma by using a combined dexamethasone suppression, and TRH stimulation test. Proc. Am. Ass. equine Practnrs. 43, 349-351.
2. Beech, J. (1999) Diseases of the pituitary gland. In: Equine Medicine and Surgery, 5th edn., Vol. 2, Eds: P.T. Colahan, A.M. Merritt, J.N. Moore, I.G. Mosby, St Louis. pp 1951-1956.
3. Beech, J. and Garcia, M. (1985) Hormonal response to thyrotropin- releasing hormone in healthy horses and in horses with pituitary adenoma. Am. J. vet. Res. 46, 1941-1943.
4. Douglas, R. (1999) Circadian cortisol rhythmicity and equine Cushing's-like disease. J. equine vet. Sci. 19, 684-752.
5. Dybdal, N.L. (1996) Endocrine and metabolic diseases. In: Large Animal Internal Medicine, 2nd edn., Ed: B.P. Smith, Mosby, St. Louis. pp 1444-1449.
6. Dybdal, N.L. (1997) Pituitary pars intermedia dysfunction (Equine Cushing's like Disease). In: Current Therapy in Equine Medicine, 4th edn., Ed: N.B. Robinson, W.B. Saunders Co., Philadelphia. pp 499-502.
7. Dybdal, N.O., Hargreaves, K.M., Madigan, J.E., Gribble, D.H., Kennedy, P.C. and Stabenfeldt, G.H. (1994) Diagnostic testing for pituitary pars intermedia dysfunction in horses. J. Am. vet. med. Ass. 204, 627-632.
8. Eiler, H., Oliver, J.W., Andrews, F.M., Fecteau, K.A., Green, E.M. and McCracken, M. (1997) Results of a combined dexamethasone suppression/ thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma. J. Am. vet. med. Ass. 211, 79-81.
9. Irvine, C.H. and Alexander, S.L. (1994) Factors affecting the circadian rhythm in plasma cortisol concentrations in the horse. Domest. Anim. Endocrinol. 11, 227-238.
10. Love, S. (1993) Equine Cushing's disease. Br. vet. J. 149, 139-153.
11. Mantis, P., Lamb, C. and Neiger, R. (2002). Effect of trilostane therapy on adrenal gland size in 13 dogs with pituitary-dependent hyperadrenocorticism: an ultrasonographic study. In: Proceedings of the 9th Meeting of the European Association of Veterinary Diagnostic Imaging. p 32.
12. Millington, W.R., Dybdal, N.O., Dawson, R., Manzini, C. and Mueller, G.P. (1988) Equine Cushing's disease: differential regulation of β-endorphin processing in tumours of the intermediate pituitary Endocrinol. 123, 1598-1604.
13. Neiger, R. and Hurley, K. (2001) 24-hour cortisol values in dogs with hyperadrenocorticism on trilostane. In: Proceedings of the 44th British Small Animal Veterinary Association Congress. p 549.
14. Neiger, R., Ramsey, I., O'Connor, J., Hurley, K.J. and Mooney, R. (2002) Trilostane treatment of 78 dogs with pituitary-dependent hyperadenocorticism. Vet. Rec. 150, 799-904.
15. Orth, D.N. and Nicholson, W.E. (1982) Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease. Endocrinol. 111, 559-563.
16. Perkins, G., Lamb, S., Erb, H.N., Schanabacher, B., Nydam, D. and Divers, T.J. (2001) Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptidine or pergolide. J. vet. intern. Med. 15, 286.
17. Peters, D.F., Erfle, J.B. and Slobojan, G.T. (1995) Low-dose pergolide mesylate treatment for equine hypophyseal adenomas (Cushing's syndrome). Proc. Am. Ass. equine Practnrs. 41, 154-155.
18. Semple, C.G., Beastall, G.H., Gray, C.E. and Thomson, J.A. (1983) Trilostane in the management of Cushing's syndrome. Acta Endocrinol. 102, 107-110.
19. Schott, H.C., Coursen, S.W., Eberhart, L.V.T., Nachreiner, R.J., Refsal, K.R., Ewart, S.L. and Marteniuk, J.V. (2001) The Michigan Cushing's project. Proc. Am. Ass. equine Practnrs. 47, 22-24.
20. Wilson, M.G., Nicholson, W.E., Holscher, M.A., Sherrell, B.J., Mount, C.D. and Orth, D.N. (1982) Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses. Endocrinol. 110, 941-54.
21. Witt, A.L. and Neiger, R. (2003) Endogenous plasma adrenocorticotrophic hormone before and after therapy with trilostane for pituitary dependent hyperadrenocortiscism. Vet. Rec. In Press.